Impact of coronavirus infection on cognitive functions in elderly patients

DOI: https://doi.org/10.29296/25877305-2021-06-08
Download full text PDF
Issue: 
6
Year: 
2021

T. Potupchik, Candidate of Medical Sciences(1), L. Evert, MD2; Yu. Kostyuchenko(2) (1)V.F.
Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia (2)Research Institute
for Medical Problems of the North, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of
Sciences

The paper reviews information on the etiology and pathogenesis of neurological manifestations in patients who have had coronavirus infection (COVID-19). It presents the data of studies that have shown that cognitive impairment is the long-term consequences of the central nervous system. Elderly patients are more susceptible to neuropsychiatric and cognitive impairment in COVID-19, and in the case of pre-existing cognitive impairment and dementia after a coronavirus infection; they are observed to have a progression of these disorders. Early detection of neuropsychological manifestations in persons who have experienced COVID-19 can lower the risk of subsequent irreversible disorders and further neurocognitive decline. Nootropic, metabolic, and antioxidant agents with a neuroprotective effect can be recommended for correction of cognitive impairment in elderly patients.
Keywords: 
infectious diseases
neurology
coronavirus infection
COVID-19
central nervous system damage
cognitive impairment
dementia
neuroprotectors

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bezdetko N.V. Tsitikolin: novoe ob izvestnom. Mezhdunarodnyj nevrologicheskij zhurnal. 2015; 4: 90–4 [Bezdetko N.V. Citikolin: new about known. International Journal of Neurology. 2015; 4: 90–4 (in Russ.)].
  2. Veselova O.F., Krysenko L.V., Makarova M.V. i dr. Voprosy sovremennoj nauki: monografija. M.: Internauka, 2017; 22. [Veselova O.F., Krysenko L.V., Makarova M.V. et al. Questions of modern Science: monograph. M.: Internauka, 2017; 22 (in Russ.)].
  3. Gosudarstvennyj reestr lekarstvennyh sredstv [Elektronnyj resurs]. [The State Register of Medicines [Electronic resource] (in Russ.)]. URL: https://grls.rosminzdrav.ru/grls.aspx
  4. Gromova O.A., Torshin I.Ju., Stahovskaja L.V. i dr. Opyt primenenija meksidola v nevrologicheskoj praktike. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2018; 118 (10): 97–107 [Gromova O.A., Torshin I.Iu., Stakhovskaya L.V. et al. Experience with mexidol in neurological practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018; 118 (10): 97–107 (in Russ.)]. DOI. 10.17116/jnevro201811810197
  5. Kamchatnov P.R. Korrektsija kognitivnyh i emotsional'nyh rasstrojstv u bol'nyh arterial'noj gipertoniej. Russkij meditsinskij zhurnal. 2019; 7: 28–9 [Kamchatnov P.R. Correction of cognitive and emotional disorders in patients with arterial hypertension. Russian Medical Journal. 2019; 7: 28–9 (in Russ.)].
  6. Krasnov V.S. Aktovegin v terapii kognitivnyh narushenij u patsientov, perenesshih novuju koronavirusnuju infektsiju COVID-19 (opyt klinicheskih nabljudenij). Effektivnaja farmakoterapija. 2021; 17 (6): 8–12 [Krasnov V.S. Actovegin in the Treatment of Cognitive Impairment in Patients After COVID-19 (Clinical Experience). Effective pharmacotherapy. 2021; 17 (6): 8–12 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-6-8-12
  7. Kudlaj D.A., Shirobokov Ja.E., Gladunova E.P. i dr. Diagnostika COVID-19. Sposoby i problemy obnaruzhenija virusa SARSCoV-2 v uslovijah pandemii. Vrach. 2020; 31 (8): 5–10 [Kudlay D., Shirobokov Ya., Gladunova E. et al. Diagnosis of COVID-19. Methods and problems of virus SARS-CoV-2 detection under pandemic conditions. Vrach. 2020; 31 (8): 5–10 (in Russ.)]. DOI: 10.29296/25877305-2020-08-01
  8. Mazin P.V., Sheshunov I.V., Mazina N.K. Metaanaliticheskaja otsenka klinicheskoj effektivnosti tsitoflavina pri nevrologicheskih zabolevanijah. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2017; 117 (3): 28–39 [Mazin P.V., Sheshunov I.V., Mazina N.K. Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017; 117 (3): 28–39 (in Russ.)]. DOI. 10.17116/jnevro20171173128-39
  9. Pizova N.V., Pizov N.A., Pizov A.V. Kognitivnye narushenija u lits, perenesshih COVID-19. Meditsinskij sovet. 2021; 4: 69–77 [Pizova N.V., Pizov N.A., Pizov A.V. Cognitive impairment in COVID-19 survivors. Meditsinskiy sovet = Medical Council. 2021; 4: 69–77 (in Russ.)]. DOI: 10.21518/2079-701X-2021-4-69-77
  10. Potupchik T.V., Veselova O.F., Evert L.S. Farmakodinamicheskie aspekty primenenija nekotoryh nootropnyh sredstv pri kognitivnyh narushenijah. Farmateka. 2014; 13: 90–5 [Potupchik T.V., Veselova O.F., Evert L.S. Pharmacodynamic aspects of use of some nootropics in cognitive disorders. Farmateka. 2014; 13: 90–5 (in Russ.)].
  11. Chukanova E.I., Chukanova A.S. Holina al'fostserat (deletsit) kak odno iz napravlenij lechenija kognitivnyh rasstrojstv. Meditsinskij alfavit. 2016; 14: 12–6 [Chukanova E.I., Chukanova A.S. Choline alfoscerate (delecit) as one of treatment areas of cognitive disorders. Medical Alphabet. 2016; 14: 12–6 (in Russ.)].
  12. Almeria M., Cejudo J.C., Sotoca J. et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020; 9: 100163. DOI: 10.1016/j.bbih.2020.100163
  13. Alonso-Lana S., Marquié M., Ruiz A. et al. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020; 12: 588872. DOI: 10.3389/fnagi.2020.588872
  14. Annweiler C., Bourgeais A., Faucon E. et al. Neurological, Cognitive, and Behavioral Disorders during COVID-19: The Nitric Oxide Track. J Am Geriatr Soc. 2020; 68 (9): 1922–3. DOI: 10.1111/jgs.16671
  15. Beaud V., Crottaz-Herbette S., Dunet V. et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021; 92 (5): 567–8. DOI: 10.1136/jnnp-2020-325173
  16. Delorme C., Paccoud O., Kas A. et al. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. CoCo-Neurosciences study group and COVID SMIT PSL study group. Eur J Neurol. 2020; 27 (12): 2651–7. DOI: 10.1111/ene.14478
  17. El H.M., Altintas E., Chapelet G. et al. High depression and anxiety in people with Alzheimer’s disease living in retirement homes during the COVID-19 crisis. Psychiatry Res. 2020; 291: 113294. DOI: 10.1016/j.psychres.2020.113294
  18. Helms J., Kremer S., Merdji H. et al. Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Crit Care. 2020; 24 (1): 491. DOI: 10.1186/s13054-020-03200-1
  19. Heneka M.T., Golenbock D., Latz E. et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020; 12 (1): 69. DOI: 10.1186/s13195-020-00640-3
  20. Malkova A., Kudlay D., Kudryavtsev I. et al. Immunogenetic Predictors of Severe COVID-19. Vaccines. 2021; 9: 211. DOI: 10.3390/vaccines9030211
  21. Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020; 12 (1): 170. DOI: 10.1186/s13195-020-00744-w
  22. Negrini F., Ferrario I., Mazziotti D. et al. Neuropsychological Features of Severe Hospitalized Coronavirus Disease 2019 Patients at Clinical Stability and Clues for Postacute Rehabilitation. Arch Phys Med Rehabil. 2021; 102 (1): 155–8. DOI: 10.1016/j.apmr.2020.09.376
  23. Riordan P., Stika M., Goldberg J. et al. COVID-19 and clinical neuropsychology: A review of neuropsychological literature on acute and chronic pulmonary disease. Clin Neuropsychol. 2020; 34 (7–8): 1480–97. DOI: 10.1080/13854046.2020.1810325
  24. Sepúlveda-Loyola W., Rodriguez-Sánchez I., Pérez-Rodriguez P. et al. Impact of Social Isolation Due to COVID-19 on Health in Older People: Mental and Physical Effects and Recommendations. J Nutr Health Aging. 2020; 24 (9): 938–47. DOI: 10.1007/s12603-020-1469-2
  25. Serrano-Castro P.J., Estivill-Torrús G., Cabezudo-Garcia P. et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia. 2020; 35 (4): 245–51. DOI: 10.1016/j.nrl.2020.04.002
  26. Soltani Z.H., Gorji A., Ghadiri T.A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View. Mol Neurobiol. 2021; 58 (2): 536–49. DOI: 10.1007/s12035-020-02149-0
  27. Stefano G.B., Ptacek R., Ptackova H. et al. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes that Favor Viral Survival. Med Sci Monit. 2021; 27: e930886. DOI: 10.12659/MSM.930886
  28. Varatharaj A., Thomas N., Ellul M.A. et al. CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020; 7 (10): 875–82. DOI: 10.1016/S2215-0366(20)30287-X
  29. Xiong J., Lipsitz O., Nasri F. et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020; 277: 55–64. DOI: 10.1016/j.jad.2020.08.001
  30. Zhou H., Lu S., Chen J., et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020; 129: 98–102. DOI: 10.1016/j.jpsychires.2020.06.022
  31. Zhou J., Liu C., Sun Y. et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021; 91: 383–92. DOI: 10.1016/j.bbi.2020.10.019